Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $19.99 USD
Change Today -1.12 / -5.31%
Volume 51.9K
OCUL On Other Exchanges
As of 2:15 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

ocular therapeutix inc (OCUL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/15 - $44.19
52 Week Low
07/31/14 - $11.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ocular therapeutix inc (OCUL) Related Businessweek News

No Related Businessweek News Found

ocular therapeutix inc (OCUL) Details

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions during cataract surgery. The company is involved in developing OTX-DP that is in Phase III clinical trials for post-surgical ocular inflammation and pain; and is in Phase II clinical trials for the treatment of inflammatory dry eye disease, as well as that has completed Phase II clinical trials for the treatment of allergic conjunctivitis. It is also developing OTX-TP, which is in Phase IIb clinical trials for glaucoma and ocular hypertension; OTX-MP product candidate that has completed Phase I clinical trials for the treatment of ocular infection indication; and Anti-VEGF hydrogel depot, an injectable hydrogel depot that is in preclinical studies. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

74 Employees
Last Reported Date: 06/2/15
Founded in 2006

ocular therapeutix inc (OCUL) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $788.8K
Chief Financial Officer and Chief Accounting ...
Total Annual Compensation: $325.5K
Chief Operating Officer
Total Annual Compensation: $510.3K
Executive Vice President of Clinical, Regulat...
Total Annual Compensation: $321.5K
Compensation as of Fiscal Year 2014.

ocular therapeutix inc (OCUL) Key Developments

Ocular Therapeutix, Inc. Announces Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis

Ocular Therapeutix, Inc. announced enrollment of the first patients in a Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA™ (sustained release dexamethasone, 0.4mg) for the treatment of allergic conjunctivitis. DEXTENZA is administered by a physician as a bioresorbable intracanalicular depot for drug release to the ocular surface for up 30 days. This prospective, US based multicenter, 1:1 randomized, parallel-arm, double-masked, vehicle-controlled study is enrolling subjects who exhibit chronic signs and symptoms of allergic conjunctivitis. This is the first of two Phase 3 studies and will evaluate DEXTENZA versus a placebo vehicle punctum plug using Ora’s modified Conjunctival Allergen Challenge (Ora-CAC®) Model (Ora, Inc., Andover, MA) which accommodates for the longer therapeutic effect of a one-time administered sustained release drug product. The study is designed to assess the effect of DEXTENZA compared with placebo on allergic reactions using three series of successive allergen challenges over a 30-day period. DEXTENZA or placebo will be administered 48 to 72 hours after final confirmatory exposure to the allergen, and the primary endpoints to be evaluated are ocular itching and conjunctival redness at day 7 following insertion. The secondary efficacy measures for both itching and redness are measured at day 14 following insertion and on days 27-30 post-insertion.

Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter of 2015

Ocular Therapeutix, Inc. reported earnings results for the first quarter of 2015. For the quarter, the company reported an increase in first quarter revenues from the same period a year ago as it prepares to submit a New Drug Application for its OTX-DP in the treatment of post-surgical ocular pain. The company reported a net loss of approximately $7.6 million, or $0.35 per share, compared to the loss of $7.0 million, or $2.45 per share, for first quarter 2014. Total revenues of $426,000 were up from $27,000 in the same period a year ago.

Ocular Therapeutix, Inc., Q1 2015 Earnings Call, May 15, 2015

Ocular Therapeutix, Inc., Q1 2015 Earnings Call, May 15, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCUL:US $19.99 USD -1.12

OCUL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCUL.
View Industry Companies

Industry Analysis


Industry Average

Valuation OCUL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 367.6x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 354.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULAR THERAPEUTIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at